Identification of potent and selective cathepsin S inhibitors containing different central cyclic scaffolds.

J Med Chem

Discovery Chemistry, ‡Cardiovascular and Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, Basel CH-4070, Switzerland.

Published: December 2013

Starting from the weakly active dual CatS/K inhibitor 5, structure-based design supported by X-ray analysis led to the discovery of the potent and selective (>50,000-fold vs CatK) cyclopentane derivative 22 by exploiting specific ligand-receptor interactions in the S2 pocket of CatS. Changing the central cyclopentane scaffold to the analogous pyrrolidine derivative 57 decreased the enzyme as well as the cell-based activity significantly by 24- and 69-fold, respectively. The most promising scaffold identified was the readily accessible proline derivative (e.g., 79). This compound, with an appealing ligand efficiency (LE) of 0.47, included additional structural modifications binding in the S1 and S3 pockets of CatS, leading to favorable in vitro and in vivo properties. Compound 79 reduced IL-2 production in a transgenic DO10.11 mouse model of antigen presentation in a dose-dependent manner with an ED50 of 5 mg/kg.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm401528kDOI Listing

Publication Analysis

Top Keywords

potent selective
8
identification potent
4
selective cathepsin
4
cathepsin inhibitors
4
inhibitors central
4
central cyclic
4
cyclic scaffolds
4
scaffolds starting
4
starting weakly
4
weakly active
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!